If you have been reading about acetylated peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
=== Drug-drug interactions === Lamividine/zidovudine interacts with stavudine and zalcitabine by competing intracellularly for activation and results in inhibiting phosphorylation. There is also a known interaction with nephrotoxic or bone marrow suppressive agents (e.g. doxorubicin) which increases the risk of hematologic toxicity of zidovudine. Monitoring renal function and hematologic tests can be used to assess these potential interactions.
== Research and career == In 1975, Theo Wallimann completed his Ph.D. Dissertation on “M-line-bound Creatine Kinase and Myofibrillar Structure” in the laboratory of Prof. Hans M. Eppenberger at the Institute of Cell Biology at ETH Zurich with distinction and received the ETH prize and medal. From 1975 - 1981, Wallimann worked as a post-doctoral research associate with Andrew G. Szent-Györgyi , at the Biology Department of Brandeis University on the subject of "Myosin-linked calcium regulation of muscle contraction". After rejoining the Biology Dept of the ETH-Zurich in 1981, Wallimann became a Lecturer in 1984 with his Habilitation on: "Localization and function of M-line-bound creatine kinase: M-band model and Phospho-Creatine Shuttle"). In 1994, Wallimann was awarded the title of Professor and in the next two years he became Head and Deputy Head of the Institute of Cell Biology. Wallimann resigned from his post in June 2008 and is now Emeritus and member of the ETH Alumni organisation. In 2005, Wallimann was awarded with the Alfred-Vogt-Prize in 2005 and in 2023, 2024 and 2025 he received the Research.com Recognition Leader Award for Biology and Biochemistry in Switzerland. In 2025, Theo Wallimann has been honored by the International Society of Sports Nutrition with a “Life-time Achievement Award” for his research on the «Creatine Kinase System and Creatine», at the Internatl. Congress on «Creatine for Health», held during March 12th-16th 2025 in Munich, Germany: https://creatineforhealth.com/creatine-conference-2025/
== Production process == Stock cubes are made by mixing already-dry ingredients into a paste, including salt, fat, (meat/bone/vegetable) extract, etc. The ingredients are usually mixed in a container (batch mixing), left to mature, and then shaped into the cube form. Alternatively, they can be mixed directly into an extruder. The "extract" portion needs to be separately produced from the meat, bone, or whatever food is intended to be used in the reconstituted boullion (see meat extract). This is achieved by large-scale cooking similar to what is used to make pre-packaged broth, followed by an evaporation process to condense the product.
The RTG was invented in 1954 by Mound Laboratories scientists Kenneth (Ken) C. Jordan (1921–2008) and John Birden (1918–2011). They were inducted into the National Inventors Hall of Fame in 2013. Jordan and Birden worked on an Army Signal Corps contract (R-65-8- 998 11-SC-03-91) beginning on 1 January 1957, to conduct research on radioactive materials and thermocouples suitable for the direct conversion of heat to electrical energy using polonium-210 as the heat source. RTGs were developed in the US during the late 1950s by Mound Laboratories in Miamisburg, Ohio, under contract with the United States Atomic Energy Commission. The project was led by Dr. Bertram C. Blanke. The first RTG launched into space by the United States was SNAP 3B in 1961 powered by 96 grams of plutonium-238 metal, aboard the Navy Transit 4A spacecraft. One of the first terrestrial uses of RTGs was in 1966 by the US Navy at uninhabited Fairway Rock in Alaska. RTGs were used at that site until 1995. A common RTG application is spacecraft power supply. Several generations of RTG design have been used for probes that traveled far from the Sun, rendering solar panels impractical. As such, they have been used for Pioneer 10 and 11; Voyager 1 and 2; Galileo; Ulysses; Cassini; New Horizons; and are planned for the Dragonfly mission to Titan. RTGs were also used instead of solar panels to power the two Viking landers, and for the scientific experiments left on the Moon by the crews of Apollo 12 through 17 (SNAP 27s).
=== Metalorganic addition === Interaction of ethylene oxide with organomagnesium compounds, which are Grignard reagents, can be regarded as nucleophilic substitution influenced by carbanion organometallic compounds. The final product of the reaction is a primary alcohol:
Sources: en.wikipedia.org
=== Saudi Arabia === The Armed Forces of Saudi Arabia uses a combat meal that is packed inside a brown plastic bag about the size and shape of an American MRE pouch. It contains a small can of tuna, a small can of sardines or salmon or beef, a small can of cheese or thickened cream, an envelope of instant noodle soup, hard crackers and dry toast (like Zwieback), a small bag of raisins or dried fruit, a small package of dates, a small bag of nuts, plus instant coffee, tea bags, sugar packets, matches, and a bag of spiced dried chickpea powder.
While personal and impersonal values often align, they can diverge, for example, if an individual seeks personal gain that is bad from a wider perspective. The exact relation between these two types of value is disputed. According to one proposal, impersonal value is the sum of all personal values. Well-being is typically understood as an intrinsic or final value, meaning that it is good in itself, independent of external factors. Things with instrumental value, by contrast, are only good as means leading to other good things, like the value of money. Well-being is further distinguished from moral, religious, and aesthetic values, which describe what is ethically right, sacred, or beautiful. Well-being may or may not overlap with other values. For instance, donating money to a charity may be morally good, even if it does not increase the donor's well-being. The terms quality of life, good life, welfare, prudential value, personal good, and individual utility are often used as synonyms for well-being. Similarly, the words pleasure, life satisfaction, and happiness are employed in overlapping ways with well-being. However, their precise meanings differ in technical contexts like philosophy and psychology: pleasure refers to individual feelings about what is attractive; life satisfaction is a positive attitude a person has towards their life as a whole; happiness is sometimes identified with life satisfaction or understood as a positive balance of pleasure over pain. Well-being is a crucial goal of many human endeavors on both individual and societal levels.
Biosynthetic human insulin (insulin human rDNA, INN) for clinical use is manufactured by recombinant DNA technology. Biosynthetic human insulin has increased purity when compared with extractive animal insulin, enhanced purity reducing antibody formation. Researchers have succeeded in introducing the gene for human insulin into plants as another method of producing insulin ("biopharming") in safflower. This technique is anticipated to reduce production costs. Several analogs of human insulin are available. These insulin analogs are closely related to the human insulin structure, and were developed for specific aspects of glycemic control in terms of fast action (prandial insulins) and long action (basal insulins). The first biosynthetic insulin analog was developed for clinical use at mealtime (prandial insulin), Humalog (insulin lispro), it is more rapidly absorbed after subcutaneous injection than regular insulin, with an effect 15 minutes after injection. Other rapid-acting analogues are NovoRapid and Apidra, with similar profiles. All are rapidly absorbed due to amino acid sequences that will reduce formation of dimers and hexamers (monomeric insulins are more rapidly absorbed). Fast acting insulins do not require the injection-to-meal interval previously recommended for human insulin and animal insulins. The other type is long acting insulin; the first of these was Lantus (insulin glargine). These have a steady effect for an extended period from 18 to 24 hours. Likewise, another protracted insulin analogue (Levemir) is based on a fatty acid acylation approach.
=== Further reading === Bourne PE, Shindyalov IN. (2003): Structure Comparison and Alignment. In: Bourne, P.E., Weissig, H. (Eds): Structural Bioinformatics. Hoboken NJ: Wiley-Liss. ISBN 0-471-20200-2 Yuan X, Bystroff C. (2004) "Non-sequential Structure-based Alignments Reveal Topology-independent Core Packing Arrangements in Proteins", Bioinformatics. Nov 5, 2004 Jung J, Lee B (2000). "Protein structure alignment using environmental profiles". Protein Eng. 13 (8): 535–543. doi:10.1093/protein/13.8.535. PMID 10964982. Ye Y, Godzik A (2005). "Multiple flexible structure alignment using partial order graphs". Bioinformatics. 21 (10): 2362–2369. doi:10.1093/bioinformatics/bti353. PMID 15746292. Sippl M, Wiederstein M (2008). "A note on difficult structure alignment problems". Bioinformatics. 24 (3): 426–427. doi:10.1093/bioinformatics/btm622. PMID 18174182.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.